Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Jul;60(1):116–120. doi: 10.1038/bjc.1989.233

Acute and cumulative effects of carboplatin on renal function.

D T Sleijfer 1, E F Smit 1, S Meijer 1, N H Mulder 1, P E Postmus 1
PMCID: PMC2247337  PMID: 2679841

Abstract

Carboplatin, a cisplatinum analogue, has no reported nephrotoxicity in phase I/II studies, assessed by creatinine clearance. We prospectively determined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400 mg m-2 day 1 and vincristine 2 mg day 1 and 8 every 4 weeks (max. five cycles) by means of clearance studies with 125I-sodium thalamate and 131I-hippurate to determine GFR and ERPF respectively. Tubular damage was monitored by excretion of tubular enzymes and relative beta 2-microglobulin clearance. During the first course no changes in renal function were seen. After the second course a significant fall in GFR and ERPF started, ultimately leading to a median decrease in GFR of 19.0% (range 6.8-38.7%) and in ERPF of 14% (range 0-38.9%). No increases in the excretion of tubular enzymes or changes in the relative beta 2-microglobulin clearances were seen. We conclude from our data that carboplatin causes considerable loss of renal function. Monitoring renal function in patients treated with multiple courses of carboplatin is warranted.

Full text

PDF
116

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bodenner D. L., Dedon P. C., Keng P. C., Katz J. C., Borch R. F. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Cancer Res. 1986 Jun;46(6):2751–2755. [PubMed] [Google Scholar]
  2. Burchenal J. H., Kalaher K., Dew K., Lokys L. Rationale for development of platinum analogs. Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1493–1498. [PubMed] [Google Scholar]
  3. Calvert A. H., Harland S. J., Newell D. R., Siddik Z. H., Jones A. C., McElwain T. J., Raju S., Wiltshaw E., Smith I. E., Baker J. M. Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982;9(3):140–147. doi: 10.1007/BF00257742. [DOI] [PubMed] [Google Scholar]
  4. Daugaard G., Rossing N., Rørth M. Effects of cisplatin on different measures of glomerular function in the human kidney with special emphasis on high-dose. Cancer Chemother Pharmacol. 1988;21(2):163–167. doi: 10.1007/BF00257365. [DOI] [PubMed] [Google Scholar]
  5. Dentino M., Luft F. C., Yum M. N., Williams S. D., Einhorn L. H. Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer. 1978 Apr;41(4):1274–1281. doi: 10.1002/1097-0142(197804)41:4<1274::aid-cncr2820410410>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  6. Egorin M. J., Van Echo D. A., Olman E. A., Whitacre M. Y., Forrest A., Aisner J. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 1985 Dec;45(12 Pt 1):6502–6506. [PubMed] [Google Scholar]
  7. Egorin M. J., Van Echo D. A., Tipping S. J., Olman E. A., Whitacre M. Y., Thompson B. W., Aisner J. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984 Nov;44(11):5432–5438. [PubMed] [Google Scholar]
  8. Elferink F., van der Vijgh W. J., Klein I., Pinedo H. M. Interaction of cisplatin and carboplatin with sodium thiosulfate: reaction rates and protein binding. Clin Chem. 1986 Apr;32(4):641–645. [PubMed] [Google Scholar]
  9. Evrin P. E., Peterson P. A., Wide L., Berggård I. Radioimmunoassay of 2 -microglobulin in human biological fluids. Scand J Clin Lab Invest. 1971 Dec;28(4):439–443. doi: 10.3109/00365517109095721. [DOI] [PubMed] [Google Scholar]
  10. Fish R. G., Shelley M. D., Griffiths H., Adams M. Re: Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1987 Jul 1;47(13):3606–3607. [PubMed] [Google Scholar]
  11. Gaver R. C., George A. M., Deeb G. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin. Cancer Chemother Pharmacol. 1987;20(4):271–276. doi: 10.1007/BF00262576. [DOI] [PubMed] [Google Scholar]
  12. Gore M. E., Calvert A. H., Smith L. E. High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study. Eur J Cancer Clin Oncol. 1987 Sep;23(9):1391–1397. doi: 10.1016/0277-5379(87)90125-8. [DOI] [PubMed] [Google Scholar]
  13. Goren M. P., Wright R. K., Horowitz M. E. Cumulative renal tubular damage associated with cisplatin nephrotoxicity. Cancer Chemother Pharmacol. 1986;18(1):69–73. doi: 10.1007/BF00253068. [DOI] [PubMed] [Google Scholar]
  14. Harland S. J., Newell D. R., Siddik Z. H., Chadwick R., Calvert A. H., Harrap K. R. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res. 1984 Apr;44(4):1693–1697. [PubMed] [Google Scholar]
  15. Lelieveld P., Van der Vijgh W. J., Veldhuizen R. W., Van Velzen D., Van Putten L. M., Atassi G., Danguy A. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives. Eur J Cancer Clin Oncol. 1984 Aug;20(8):1087–1104. doi: 10.1016/0277-5379(84)90112-3. [DOI] [PubMed] [Google Scholar]
  16. Leyvraz S., Ohnuma T., Lassus M., Holland J. F. Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin Oncol. 1985 Oct;3(10):1385–1392. doi: 10.1200/JCO.1985.3.10.1385. [DOI] [PubMed] [Google Scholar]
  17. Madias N. E., Harrington J. T. Platinum nephrotoxicity. Am J Med. 1978 Aug;65(2):307–314. doi: 10.1016/0002-9343(78)90825-2. [DOI] [PubMed] [Google Scholar]
  18. Markman M., Cleary S., Howell S. B. Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection. Eur J Cancer Clin Oncol. 1985 Sep;21(9):1015–1018. doi: 10.1016/0277-5379(85)90285-8. [DOI] [PubMed] [Google Scholar]
  19. Meijer S., Sleijfer D. T., Mulder N. H., Sluiter W. J., Marrink J., Koops H. S., Brouwers T. M., Oldhoff J., van der Hem G. K., Mandema E. Some effects of combination chemotherapy with cis-platinum on renal function in patients with nonseminomatous testicular carcinoma. Cancer. 1983 Jun 1;51(11):2035–2040. doi: 10.1002/1097-0142(19830601)51:11<2035::aid-cncr2820511113>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  20. Offerman J. J., Mulder N. H., Sleijfer D. T., Meijer S., Koops H. S., Donker A. J., van der Hem G. K. Influence of captopril on cis-diamminedichloroplatinum-induced renal toxicity. Am J Nephrol. 1985;5(6):433–436. doi: 10.1159/000166978. [DOI] [PubMed] [Google Scholar]
  21. Owens S. E., Thatcher N., Sharma H., Adam N., Harrison R., Smith A., Zaki A., Baer J. C., McAuliffe C. A., Crowther D. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-trans-dichlorodihydroxy-bis-(isopropylamine) platinum(IV), cis-dichloro-bis-cyclopropylamine platinum(II), and cis-diammine 1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a gamma camera. Cancer Chemother Pharmacol. 1985;14(3):253–257. doi: 10.1007/BF00258128. [DOI] [PubMed] [Google Scholar]
  22. Rozencweig M., Nicaise C., Beer M., Crespeigne N., Van Rijmenant M., Lenaz L., Kenis Y. Phase I study of carboplatin given on a five-day intravenous schedule. J Clin Oncol. 1983 Oct;1(10):621–626. doi: 10.1200/JCO.1983.1.10.621. [DOI] [PubMed] [Google Scholar]
  23. Skillen A. W., Buamah P. K., Cantwell B. M., Cornell C., Hodson A. W., Harris A. L. Urinary protein and enzyme excretion in patients receiving chemotherapy with the cis-platinum analogs carboplatin (CBDCA, JM8) and iproplatin (CHIP, JM9). Cancer Chemother Pharmacol. 1988;22(3):228–234. doi: 10.1007/BF00273416. [DOI] [PubMed] [Google Scholar]
  24. Stewart D. J., Mikhael N. Z., Nanji A. A., Nair R. C., Kacew S., Howard K., Hirte W., Maroun J. A. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity. J Clin Oncol. 1985 Sep;3(9):1251–1256. doi: 10.1200/JCO.1985.3.9.1251. [DOI] [PubMed] [Google Scholar]
  25. Van Echo D. A., Egorin M. J., Whitacre M. Y., Olman E. A., Aisner J. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days. Cancer Treat Rep. 1984 Sep;68(9):1103–1114. [PubMed] [Google Scholar]
  26. Von Hoff D. D. Whither carboplatin?--A replacement for or an alternative to cisplatin? J Clin Oncol. 1987 Feb;5(2):169–171. doi: 10.1200/JCO.1987.5.2.169. [DOI] [PubMed] [Google Scholar]
  27. van Glabbeke M., Renard J., Pinedo H. M., Cavalli F., Vermorken J., Sessa C., Abele R., Clavel M., Monfardini S. Iproplatin and carboplatin induced toxicities: overview of phase II clinical trial conducted by the EORTC Early Clinical Trials Cooperative Group (ECTG). Eur J Cancer Clin Oncol. 1988 Feb;24(2):255–262. doi: 10.1016/0277-5379(88)90262-3. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES